Cadex Genomics has developed Alibrex, a blood-based assay that indicates when a patient with a stage IV solid tumor cancer is not responding to therapy within two weeks after treatment commences
REDWOOD CITY, CA, UNITED STATES - Mar 12, 2019 -
Cadex Genomics, Corp.
announced that it has initiated a pivotal clinical study designed to validate the ability of Alibrex to act as a biomarker for predicting early non-response to therapy in stage IV cancer patients. Rocky Mountain Cancer Centers will be the first center to enroll patients. The multi-center study will involve over 500 patients with metastatic non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (CRC).
We are excited to work with Dr. Cohn and Rocky Mountain Cancer Centers on this study. RMCC is a highly regarded leader in cancer-related clinical studies, said Bill Haack, CEO at Cadex Genomics. We want to make Alibrex available to physicians who treat stage IV CRC and NSCLC cancer patients so they can quickly determine when patients are not responding to therapy, allowing a more accurate and earlier informed decision regarding other treatment options."
Unlike mutational analysis tests, Alibrex does not predict which therapy may work before the therapy is administered. Alibrex determines when therapy is not working shortly after a patient receives the first dose of therapy. Alibrex gives physicians rapid feedback on the patients tumor response to therapy regardless of whether the treatment involves an immunotherapy agent, a targeted therapy or a cytotoxic therapy agent.
Preliminary studies with Alibrex show strong potential for providing a genomic indicator of cancer therapy ineffectiveness or effectiveness early in the treatment cycle, said Dr. Allen Cohn, Medical Director of Research at the Rocky Mountain Cancer Centers in Denver. Matching mutational analysis, prior to therapy, with a mutation-agnostic therapy diagnostic like Alibrex after the first cycle of treatment will allow physicians to guide cancer therapy for patients on a real-time basis.
Alibrex is a patented technology that detects, with great analytical precision, retrotransposon elements found on all 23 chromosomes. Alibrex enables testing with most tumor types. Alibrex is based on qPCR technology and delivers fast turnaround time.
About Cadex Genomics
Cadex Genomics is a privately-held molecular diagnostic assay company based in Redwood City, California that is improving cancer patient outcomes by providing physicians with better diagnostic tools to guide treatment.
For more information, please visit our website
. Alibrex and Cadex Genomics are trademarks of Cadex Genomics, Corp.
About Rocky Mountain Cancer Centers
Rocky Mountain Cancer Centers is Colorado's largest and most comprehensive provider of cancer care with 54 physicians treating patients in 21 community-based locations across the state. We are united in healing with The US Oncology Network, one of the nation's largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based patient care.
Cadex Genomics Media Contact: Greg Schafer, Chief Commercial Officer